Pharvaris N.V. - Ordinary Shares (NQ:PHVS)

31.63 +1.49 (+4.94%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jun 4, 2026 Add to My Watchlist

Price and Volume

Volume	361,808
Open	29.99
Bid (Size)	27.60 (100)
Ask (Size)	33.50 (100)
Prev. Close	30.14
Today's Range	29.56 - 32.20
52wk Range	15.91 - 33.33
Shares Outstanding	33,816,459
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026

May 29, 2026

From Pharvaris N.V.

Via GlobeNewswire

Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares ↗

May 19, 2026

This clinical-stage biotech develops therapies for rare muscle diseases, leveraging its FORCE platform to target significant unmet needs.

Via The Motley Fool

Performance

YTD	+19.4%	+19.4%
1 Month	+5.4%	+5.4%
3 Month	+18.0%	+18.0%
6 Month	+7.7%	+7.7%
1 Year	+83.0%	+83.0%

More News

What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors ↗

May 19, 2026

Via The Motley Fool

Pharvaris NV (NASDAQ:PHVS) Reports Q4 2025 Financial Results and Key Pipeline Milestones ↗

April 02, 2026

Via Chartmill

Pharvaris Reports First Quarter 2026 Financial Results and Provides Business Update

May 12, 2026

From Pharvaris N.V.

Via GlobeNewswire

Pharvaris Chief Medical Officer Sells 14,000 Shares for $427,000 ↗

May 11, 2026

Via The Motley Fool

Pharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares

May 11, 2026

From Pharvaris N.V.

Via GlobeNewswire

Pharvaris Announces Pricing of $115 Million Underwritten Offering of Ordinary Shares

May 08, 2026

From Pharvaris N.V.

Via GlobeNewswire

For Pharvaris Investors, the Director's Sale Matters Less Than What's Coming Next ↗

April 29, 2026

Via The Motley Fool

Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference

April 20, 2026

From Pharvaris N.V.

Via GlobeNewswire

Pharvaris' CEO Dumped Over 23,000 Company Shares. Here's What That Means for Investors. ↗

April 13, 2026

Via The Motley Fool

Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

April 02, 2026

From Pharvaris N.V.

Via GlobeNewswire

Evidence of Efficacy and Safety of Deucrictibant for Prophylaxis and On-Demand Treatment of Hereditary Angioedema Attacks Published Back-to-Back in The Lancet Haematology

March 20, 2026

From Pharvaris N.V.

Via GlobeNewswire

Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit ↗

March 18, 2026

Via The Motley Fool

Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit ↗

March 18, 2026

Via The Motley Fool

Validation of Patient-Reported Outcomes in the On-Demand Treatment of Hereditary Angioedema Attacks Published in Clinical Reviews in Allergy & Immunology

March 11, 2026

From Pharvaris N.V.

Via GlobeNewswire

Deucrictibant Data Supporting Potentially Differentiated Profile for the On-Demand and Prophylactic Treatment of Bradykinin-Mediated Angioedema Presented at AAAAI 2026

March 02, 2026

From Pharvaris N.V.

Via GlobeNewswire

Pharvaris to Present Clinical Data at the AAAAI 2026 Annual Meeting

February 10, 2026

From Pharvaris N.V.

Via GlobeNewswire

Pharvaris Outlines 2026 Strategic Priorities

January 12, 2026

From Pharvaris N.V.

Via GlobeNewswire

This Biotech Fund Just Made a $22 Million Bet on Pharvaris Stock — Is It a Buy? ↗

December 09, 2025

Via The Motley Fool

Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares ↗

December 08, 2025

Via The Motley Fool

PHVS Stock Jumps After Phase 3 Trial Shows Rapid Symptom Relief For Oral HAE Treatment ↗

December 03, 2025

Via Stocktwits

Pharvaris Announces Positive Topline Data from RAPIDe-3 Pivotal Study Confirming Potential of Deucrictibant for On-Demand Treatment of HAE Attacks

December 03, 2025

From Pharvaris N.V.

Via GlobeNewswire

A $68 Million Signal: What General Atlantic Sees in Pharvaris Right Now ↗

December 02, 2025

Via The Motley Fool

What One Fund's Sale of Centessa Stock Signals About the Fast-Rising Biotech Company ↗

November 29, 2025

Via The Motley Fool

Frequently Asked Questions

Is Pharvaris N.V. - Ordinary Shares publicly traded?

Yes, Pharvaris N.V. - Ordinary Shares is publicly traded.

What exchange does Pharvaris N.V. - Ordinary Shares trade on?

Pharvaris N.V. - Ordinary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Pharvaris N.V. - Ordinary Shares?

The ticker symbol for Pharvaris N.V. - Ordinary Shares is PHVS on the Nasdaq Stock Market

What is the current price of Pharvaris N.V. - Ordinary Shares?

The current price of Pharvaris N.V. - Ordinary Shares is 31.63

When was Pharvaris N.V. - Ordinary Shares last traded?

The last trade of Pharvaris N.V. - Ordinary Shares was at 06/04/26 04:00 PM ET

What is the market capitalization of Pharvaris N.V. - Ordinary Shares?

The market capitalization of Pharvaris N.V. - Ordinary Shares is 1.07B

How many shares of Pharvaris N.V. - Ordinary Shares are outstanding?

Pharvaris N.V. - Ordinary Shares has 1B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.